UTMB Researchers Develop Nasal Spray Treatment for Alzheimer's Disease
Researchers at UTMB developed a nasal spray targeting tau protein build-up in Alzheimer's, improving cognitive functions in mice. This breakthrough may transform treatment strategies and lead to human clinical trials.
Read original article
Researchers at the University of Texas Medical Branch (UTMB) have made a significant advancement in Alzheimer's disease treatment by developing a nasal spray that targets harmful tau protein build-up. Published in Science Translational Medicine, the study demonstrates that this innovative approach can improve cognitive functions in aged mice models with neurodegenerative diseases. The nasal spray delivers a specific antibody, TTCM2, which selectively targets toxic tau aggregates, bypassing the blood-brain barrier and enhancing therapeutic efficacy. This method utilizes TRIM21, an intracellular receptor that aids in clearing antibody-bound tau aggregates, thereby improving cognitive outcomes in the mice. The researchers believe this breakthrough could transform treatment strategies for Alzheimer’s and related tauopathies, offering new hope for millions affected by these conditions. Future plans include conducting preclinical trials and exploring the potential of TTCM2 in human clinical trials. The study received funding from the NIH, Alzheimer’s Association, and UTMB Claude D. Pepper OAIC Pilot grant. The research team includes notable contributors such as Sagar Gaikwad, Nicha Puangmalai, Minal Sonawane, and Mauro Montalbano. This development highlights the potential for non-invasive therapies in addressing neurodegenerative diseases, marking a promising step forward in the quest for effective treatments.
Related
Hyper-Focus on Amyloid Hypothesis for Alzheimer's May Have Slowed Progress
The article critiques the overemphasis on the amyloid hypothesis in Alzheimer's research, proposing repurposing hydroxychloroquine for treatment. It highlights concerns about current drugs, fraud, and the need for diverse research approaches.
Charm creates a potent therapy candidate for fatal prion diseases
A collaboration between Broad Institute and Whitehead Institute developed CHARM, a gene-silencing tool for prion diseases. CHARMs target disease-causing genes through epigenetic editing, showing promise in mice with low toxicity. Researchers aim to optimize CHARMs for clinical trials.
'Supermodel granny' drug extends life in animals
A drug targeting interleukin-11 extended lab mice lifespans by 25%, improving health and reducing cancer rates. Human testing is ongoing, with potential anti-ageing effects sparking interest in molecular ageing mechanisms.
Anti-ageing 'supermodel granny' drug extends life in mice by 25%
A drug targeting interleukin-11 extended lab mice lifespans by 25%, improving health and reducing cancer. Its effects on human ageing are uncertain, despite promising results. Researchers aim to slow ageing by manipulating molecular processes.
New Nano-Tech to Control the Brain Using Magnetic Fields
Researchers in South Korea developed Nano-MIND technology for wireless control of brain regions using magnetic fields. This innovation offers precise modulation of deep brain circuits, potentially impacting cognition and emotion. Published in Nature Nanotechnology, the study suggests applications in neuroscience and neurological treatments.
3 commentsNasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice
Related
Hyper-Focus on Amyloid Hypothesis for Alzheimer's May Have Slowed Progress
The article critiques the overemphasis on the amyloid hypothesis in Alzheimer's research, proposing repurposing hydroxychloroquine for treatment. It highlights concerns about current drugs, fraud, and the need for diverse research approaches.
Charm creates a potent therapy candidate for fatal prion diseases
A collaboration between Broad Institute and Whitehead Institute developed CHARM, a gene-silencing tool for prion diseases. CHARMs target disease-causing genes through epigenetic editing, showing promise in mice with low toxicity. Researchers aim to optimize CHARMs for clinical trials.
'Supermodel granny' drug extends life in animals
A drug targeting interleukin-11 extended lab mice lifespans by 25%, improving health and reducing cancer rates. Human testing is ongoing, with potential anti-ageing effects sparking interest in molecular ageing mechanisms.
Anti-ageing 'supermodel granny' drug extends life in mice by 25%
A drug targeting interleukin-11 extended lab mice lifespans by 25%, improving health and reducing cancer. Its effects on human ageing are uncertain, despite promising results. Researchers aim to slow ageing by manipulating molecular processes.
New Nano-Tech to Control the Brain Using Magnetic Fields
Researchers in South Korea developed Nano-MIND technology for wireless control of brain regions using magnetic fields. This innovation offers precise modulation of deep brain circuits, potentially impacting cognition and emotion. Published in Nature Nanotechnology, the study suggests applications in neuroscience and neurological treatments.